FDA Diabetes Drug Review Slowed by Snow

Luke Timmerman2/25/10

San Diego-based Amylin Pharmaceuticals (NASDAQ: AMLN), along with partners Eli Lilly and Waltham, MA-based Alkermes (NASDAQ: ALKS), said today that the FDA deadline for reviewing a once-weekly injectable diabetes drug has been pushed back one week, to March 12, because of the mid-Atlantic snowstorm earlier this month. If approved, analysts expect the drug, exenatide once-weekly, will become a blockbuster seller as the first diabetes treatment that can be taken with less frequent, once-weekly injections.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.